Brexpiprazole: A Novel Antipsychotic for Major Depressi...
October 1, 2016 - Clinical , Featured By: Nicollette Pacheco, Staff Editor [Graphics-focused] – Brexpiprazole (REXULTI®) is a novel atypical antipsychotic that was approved in July 2015 for the adjunctive treatment of Major Depressive Disorder (MDD) and as monotherapy in schizophrenia.1 Brexpiprazole is a serotonin-dopamine activity modulator with partial agonism at serotonergic 5HT1α and dopaminergic D2 receptors, as well as potent antagonism… |
|
Medication Delivery: There’s an App for That...
October 1, 2016 - Featured , In the News / Politics By: Caitlyn Cummings, Pharm.D. and Maria Marzella Mantione, Pharm.D., CGP, FAPhA – From ordering food to requesting transportation, we trust app-based delivery services for everything, so it makes sense that medication delivery through an app would be next. Zipdrug is a new medication delivery service based in New York City which will pick-up and deliver… |
|
New Metformin Labeling Change Mandated by the FDA...
October 1, 2016 - Featured , In the News / Politics By: Jack (Hongkai) Bao, PharmD Candidate 2018 – Metformin is an oral anti-hyperglycemic agent of the biguanide class and is FDA-indicated to treat type 2 diabetes or non-insulin-dependent diabetes mellitus (NIDDM).1 Metformin works by decreasing hepatic glucose production and simultaneously increasing peripheral tissue sensitivity to insulin. Unlike other oral anti-hyperglycemic agents such as the sulfonylureas,… |
|
Risk of Using Mislabeled and Unregulated Cannabidiol Pr...
October 1, 2016 - Featured , Professional Advice / Opinions By: Zachary Piracha, Pharm.D Candidate 2017 – The following account is a case report I was involved with during my rotation at the FDA. On 06/21/16, the Consumer Complaint Coordinator division of the Food and Drug Administration (FDA) received a report from a consumer that had discovered an online seller of dietary supplements, and purchased… |